Amgen 4.9 percent and Novo Nordisk more than 3.1 percent. As part of its mission to “enhance the health and well-being of all ...
WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback